Infographic: A Guide to Briefs in the Amgen vs Sandoz Supreme Court Case

March 29, 2017
Christina Mattina

Patent disputes have continued following the approval of filgrastim-sndz (Zarxio), a biosimilar product developed by Sandoz. Amgen, which markets the reference drug filgrastim (Neupogen), now claims that Sandoz did not provide sufficient information about the biosimilar, Zarxio. Here's a timeline of where the 2 companies stands today.

Related Content:

News | Legal | Business

x